Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders

Jerry L Spivak, Hans Hasselbalch

Research output: Contribution to journalArticle

Abstract

Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplastic and non-neoplastic conditions. Hydroxycarbamide is readily absorbed and widely distributed throughout the body. It acts primarily to inhibit DNA synthesis, which underpins its use in solid tumors, viral infections and chronic myeloproliferative disorders. Hydroxycarbamide is an effective treatment for preventing transient ischemic attacks associated with thrombocytosis in chronic myeloproliferative disorders because it is a nitric oxide donor. While its mechanism of action and side-effect profile are well defined, its potential for leukemic transformation as a single agent is still a matter of controversy. Based on a search of the Medline database, this article encompasses the pharmacokinetics, pharmacodynamics, clinical use and tolerability of hydroxycarbamide, plus its potential for mutagenicity with special reference to the chronic myeloproliferative disorders. The toxicity profile of hydroxycarbamide is also discussed to enable clinicians to balance potential risks with therapeutic benefits.

Original languageEnglish (US)
Pages (from-to)403-414
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume11
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Myeloproliferative Disorders
Thrombocytosis
Nitric Oxide Donors
Transient Ischemic Attack
Virus Diseases
Antiviral Agents
Pharmacokinetics
Databases
DNA
Neoplasms
Therapeutics

Keywords

  • acute leukemia
  • essential thrombocythemia
  • hydroxycarbamide
  • polycythemia vera

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Hydroxycarbamide : A user's guide for chronic myeloproliferative disorders. / Spivak, Jerry L; Hasselbalch, Hans.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 3, 03.2011, p. 403-414.

Research output: Contribution to journalArticle

@article{89f0307a782d42c882492e3849ef8242,
title = "Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders",
abstract = "Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplastic and non-neoplastic conditions. Hydroxycarbamide is readily absorbed and widely distributed throughout the body. It acts primarily to inhibit DNA synthesis, which underpins its use in solid tumors, viral infections and chronic myeloproliferative disorders. Hydroxycarbamide is an effective treatment for preventing transient ischemic attacks associated with thrombocytosis in chronic myeloproliferative disorders because it is a nitric oxide donor. While its mechanism of action and side-effect profile are well defined, its potential for leukemic transformation as a single agent is still a matter of controversy. Based on a search of the Medline database, this article encompasses the pharmacokinetics, pharmacodynamics, clinical use and tolerability of hydroxycarbamide, plus its potential for mutagenicity with special reference to the chronic myeloproliferative disorders. The toxicity profile of hydroxycarbamide is also discussed to enable clinicians to balance potential risks with therapeutic benefits.",
keywords = "acute leukemia, essential thrombocythemia, hydroxycarbamide, polycythemia vera",
author = "Spivak, {Jerry L} and Hans Hasselbalch",
year = "2011",
month = "3",
doi = "10.1586/era.11.10",
language = "English (US)",
volume = "11",
pages = "403--414",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Hydroxycarbamide

T2 - A user's guide for chronic myeloproliferative disorders

AU - Spivak, Jerry L

AU - Hasselbalch, Hans

PY - 2011/3

Y1 - 2011/3

N2 - Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplastic and non-neoplastic conditions. Hydroxycarbamide is readily absorbed and widely distributed throughout the body. It acts primarily to inhibit DNA synthesis, which underpins its use in solid tumors, viral infections and chronic myeloproliferative disorders. Hydroxycarbamide is an effective treatment for preventing transient ischemic attacks associated with thrombocytosis in chronic myeloproliferative disorders because it is a nitric oxide donor. While its mechanism of action and side-effect profile are well defined, its potential for leukemic transformation as a single agent is still a matter of controversy. Based on a search of the Medline database, this article encompasses the pharmacokinetics, pharmacodynamics, clinical use and tolerability of hydroxycarbamide, plus its potential for mutagenicity with special reference to the chronic myeloproliferative disorders. The toxicity profile of hydroxycarbamide is also discussed to enable clinicians to balance potential risks with therapeutic benefits.

AB - Hydroxycarbamide is a nonalkylating antiproliferative and antiviral agent that has been used for over 40 years to treat a variety of neoplastic and non-neoplastic conditions. Hydroxycarbamide is readily absorbed and widely distributed throughout the body. It acts primarily to inhibit DNA synthesis, which underpins its use in solid tumors, viral infections and chronic myeloproliferative disorders. Hydroxycarbamide is an effective treatment for preventing transient ischemic attacks associated with thrombocytosis in chronic myeloproliferative disorders because it is a nitric oxide donor. While its mechanism of action and side-effect profile are well defined, its potential for leukemic transformation as a single agent is still a matter of controversy. Based on a search of the Medline database, this article encompasses the pharmacokinetics, pharmacodynamics, clinical use and tolerability of hydroxycarbamide, plus its potential for mutagenicity with special reference to the chronic myeloproliferative disorders. The toxicity profile of hydroxycarbamide is also discussed to enable clinicians to balance potential risks with therapeutic benefits.

KW - acute leukemia

KW - essential thrombocythemia

KW - hydroxycarbamide

KW - polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=79952980528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952980528&partnerID=8YFLogxK

U2 - 10.1586/era.11.10

DO - 10.1586/era.11.10

M3 - Article

C2 - 21417854

AN - SCOPUS:79952980528

VL - 11

SP - 403

EP - 414

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 3

ER -